RxDoctor Payments Data

Jay Kripalani, MD

Internal Medicine · Howard Beach, NYNPI 1902965353

Payments from drug & device makers

$2,742in general payments, 2019–2025

Across 97 payments — averaging $28.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$565
  • Abbott$425
  • Novo Nordisk$420
  • Amneal Pharmaceuticals LLC$317
  • Merck$229
  • Lilly USA, LLC$133
  • plus $653 from 10 others

What the payments were for

  • Food & beverage$2,736100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,742 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$190,861
Medicare patients
156
Services billed
3,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$25,466
EliquisApixaban12$20,149
MounjaroTirzepatide11$14,854
SynthroidLevothyroxine Sodium25$2,598
Levothyroxine Sodium60$1,840
Losartan Potassium116$1,155
Atorvastatin Calcium88$977
Valsartan23$975
Simvastatin66$969
Metoprolol Succinate55$925
Amlodipine Besylate105$814
Escitalopram Oxalate16$620
Zolpidem Tartrate67$589
Clonazepam35$568
Fentanyl12$548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$420$25,46624 claims
PfizerEliquis$121$20,14912 claims
Lilly USA, LLCMounjaro$133$14,85411 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$317$1,84060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Howard Beach

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →